EMERYVILLE, Calif., Nov. 07, 2017 -- Amyris, Inc. (Nasdaq:AMRS) today announced that it is rescheduling the release of its financial results for the third quarter ended September 30, 2017 to after market close on Tuesday, November 14, 2017.
Amyris is rescheduling its earnings call to November 14 to provide time to complete, and assess the impact of, an in-process commercial agreement. Amyris has no current plans for new financings or debt offerings.
The company will hold its quarterly conference call to discuss these results, as well as provide an update on the company's business and outlook, at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, November 14, 2017.
Conference Call:
Tuesday, November 14, 2017, 4:30 p.m. ET/1:30 p.m. PT
Dial-in Number:
(866) 516-3867 (U.S. & International)
Access Code: 9293849
Audio Webcast:
A live webcast of the call will be available online on the Amyris website. To listen via live webcast, please visit: http://investors.amyris.com. A replay of the webcast will be available on the Investor Relations section of the company's website approximately two hours after the conclusion of the call.
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.
Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as a potential commercial agreement and its impact and expectations regarding future financing activity), that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris’s liquidity and ability to fund operating and capital expenses, uncertainty regarding consummating proposed transactions, including the timing thereof, risks related to Amyris's reliance on third parties to achieve its goals, and other risks detailed in the "Risk Factors" section of Amyris's quarterly report on Form 10-Q filed on August 14, 2017. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo and No Compromise are registered trademarks of Amyris, Inc.
Contact:
Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc.
+1 (510) 740-7481
[email protected]
[email protected]


GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App
FTC Questions Apple News Over Alleged Bias Against Conservative Media
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 



